BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Executive Summary

• BioMark Diagnostics announced that its AI‑driven metabolomic model for lung cancer detection has been accepted for publication in Frontiers in Oncology.
• The research, conducted with Dr. Maria Vaida’s team at Harrisburg University, showcases a machine‑learning predictive model using pathway‑based plasma metabolites and SHAP interpretability analysis.
• The acceptance validates BioMark’s multi‑year investment in AI/ML infrastructure and reinforces its positioning at the intersection of oncology, metabolomics, and data science.

Key Details

• Publication: Article titled “Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection” accepted by Frontiers in Oncology.
• Research Focus: Machine‑learning predictive model leveraging Human Metabolome Database (HMDB) pathway features to detect early‑stage lung cancer.
• Methodology Highlights: Use of SHAP analysis for interpretability; identification of metabolic pathways linked to tumor growth and nutrient processing.
• Collaboration: Conducted with Dr. Maria Vaida and her team at Harrisburg University of Science and Technology.
• Strategic Significance: Demonstrates successful integration of AI/ML with metabolomics, providing third‑party validation of BioMark’s capital allocation to advanced computational tools.
• CEO Quote: Rashid Ahmed Bux emphasized the milestone as “third‑party validation” of AI investments and a proof of concept for AI applications in healthcare.
• Publication Timing: Full paper expected later in January 2026, to be posted on BioMark’s website.

Notable Quotes

“The acceptance of our work in Frontiers in Oncology is a pivotal moment for BioMark… it provides third‑party validation of the investments we have made in AI and machine learning over the past several years.” – Rashid Ahmed Bux, President & CEO

Materiality Assessment: Non-Material – Positive (the announcement highlights scientific progress but does not convey immediate financial impact or operational change).